Key result
Urinary thromboxane testing identifies aspirin-treated patients with suboptimal suppression and heightened atherothrombotic risk.
Why the study?
Many clinicians are unaware of the link between suboptimal aspirin response and increased risk for poor clinical outcomes, and biomarker testing for aspirin efficacy is not routinely performed.
Answers are grounded in this paper and cite their sources.
Urinary thromboxane testing may help identify suboptimal response to aspirin therapy, potentially allowing for individualized dosing to reduce atherothrombotic risk.
Biomarker testing for efficacy of therapy is an accepted way for clinicians to individualize dosing to genetic and/or environmental factors that may be influencing a treatment regimen. Aspirin is used by nearly 43 million Americans on a regular basis to reduce risks associated with various atherothrombotic diseases. Despite its widespread use, many clinicians are unaware of the link between suboptimal response to aspirin therapy and increased risk for inferior clinical outcomes in several disease states, and biomarker testing for efficacy of aspirin therapy is not performed as routinely as efficacy testing in other therapeutic areas. This article reviews the clinical and laboratory aspects of determining whole-body thromboxane production, particularly as it pertains to efficacy assessment of aspirin responsiveness.
No takes yet. Share an insight, caveat, or question.
Neath et al. (2014) conducted a review in Atherothrombotic disease. Urinary thromboxane testing (11-dehydro-TxB2) was evaluated. Urinary thromboxane testing can identify individuals on aspirin therapy who have suboptimal thromboxane suppression and remain at increased risk for atherothrombotic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: